Long-term Quality of Life Improvement in Subjects with Healed Erosive Esophagitis: Treatment with Lansoprazole

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 2009 Jul 8

PMID 19582579

Citations 2

Authors

Thomas O Kovacs

James W Freston

Marian M Haber

Stuart Atkinson

Barbara Hunt

David A Peura

Affiliations

Soon will be listed here.

Abstract

Background: Gastroesophageal reflux disease (GERD) is a chronic symptomatic condition and may be associated with erosive esophagitis (EE). Considerable data on the long-term maintenance of healing of EE are available, but data on long-term GERD symptom prevention and patient quality of life (QOL) are limited.

Aims: To investigate QOL in subjects with healed EE who received 12 months of double-blind maintenance treatment with lansoprazole or ranitidine, followed by long-term open-label lansoprazole therapy to prevent recurrence of EE.

Methods: Subjects with healed EE received 12 months of double-blind maintenance treatment with lansoprazole 15 mg once daily or ranitidine 150 mg twice daily, followed by dose-titrated, open-label lansoprazole therapy for up to 82 months.

Results: During double-blind treatment (n = 206), lansoprazole-treated patients showed significantly (P <or= 0.05) greater improvements than ranitidine-treated patients in the frequency, severity, and 'bothersomeness' of heartburn, the symptom index, problems of activity limitation, eating and drinking problems, symptom problems, health distress, and social functioning. During dose-titrated, open-label treatment (n = 195), all disease-specific QOL scales except sleep improved significantly (P < 0.001) from open-label baseline at each time-point.

Conclusions: Maintenance treatment with lansoprazole for 12 months in healed EE subjects produced significantly greater improvements in QOL indicators than ranitidine. These improvements were sustained during dose-titrated, open-label lansoprazole treatment.

Citing Articles

Deprescribing versus continuation of chronic proton pump inhibitor use in adults.

Boghossian T, Rashid F, Thompson W, Welch V, Moayyedi P, Rojas-Fernandez C Cochrane Database Syst Rev. 2017; 3:CD011969.

PMID: 28301676 PMC: 6464703. DOI: 10.1002/14651858.CD011969.pub2.

Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis.

Wittbrodt E, Baum C, Peura D Clin Exp Gastroenterol. 2011; 2:117-28.

PMID: 21694835 PMC: 3108635. DOI: 10.2147/ceg.s5765.

References

Kovacs T, Freston J, Haber M, Hunt B, Atkinson S, Peura D . Long-term efficacy of lansoprazole in preventing relapse of erosive reflux esophagitis. Dig Dis Sci. 2009; 54(8):1693-701. PMC: 2702676. DOI: 10.1007/s10620-009-0769-5. View

Revicki D, Sorensen S, Maton P, Orlando R . Health-related quality of life outcomes of omeprazole versus ranitidine in poorly responsive symptomatic gastroesophageal reflux disease. Dig Dis. 1999; 16(5):284-91. DOI: 10.1159/000016878. View

McHorney C, Ware Jr J, Raczek A . The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993; 31(3):247-63. DOI: 10.1097/00005650-199303000-00006. View

Shaw M, Crawley J . Improving health-related quality of life in gastro-oesophageal reflux disease. Drugs. 2003; 63(21):2307-16. DOI: 10.2165/00003495-200363210-00003. View

Bytzer P, Morocutti A, Kennerly P, Ravic M, Miller N . Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment. Scand J Gastroenterol. 2006; 41(10):1132-40. DOI: 10.1080/00365520600615781. View

Peura D, Freston J, Haber M, Kovacs T, Hunt B, Atkinson S . Lansoprazole for long-term maintenance therapy of erosive esophagitis: double-blind comparison with ranitidine. Dig Dis Sci. 2008; 54(5):955-63. DOI: 10.1007/s10620-008-0466-9. View

Hansen A, Bergheim R, Fagertun H, Lund H, Wiklund I, Moum B . Long-term management of patients with symptoms of gastro-oesophageal reflux disease -- a Norwegian randomised prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general.... Int J Clin Pract. 2006; 60(1):15-22. DOI: 10.1111/j.1368-5031.2006.00768.x. View

Mathias S, Castell D, Elkin E, Matosian M . Health-related quality of life of patients with acute erosive reflux esophagitis. Dig Dis Sci. 1996; 41(11):2123-9. DOI: 10.1007/BF02071390. View

Wiklund I, Bardhan K, Muller-Lissner S, Bigard M, Bianchi Porro G, Ponce J . Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group. Ital J Gastroenterol Hepatol. 1998; 30(1):19-27. View

10.

Fazio A . A concurrent validational study of the NCHS General Well-Being Schedule. Vital Health Stat 2. 1977; (73):1-53. View

11.

Kamolz T, Pointner R, Velanovich V . The impact of gastroesophageal reflux disease on quality of life. Surg Endosc. 2003; 17(8):1193-9. DOI: 10.1007/s00464-002-9229-4. View

12.

Rush D, STELMACH W, Young T, Kirchdoerfer L, Holverson H, SABESIN S . Clinical effectiveness and quality of life with ranitidine vs placebo in gastroesophageal reflux disease patients: a clinical experience network (CEN) study. J Fam Pract. 1995; 41(2):126-36. View

13.

Colwell H, Mathias S, Pasta D, Henning J, Hunt R . Development of a health-related quality-of-life questionnaire for individuals with gastroesophageal reflux disease: a validation study. Dig Dis Sci. 1999; 44(7):1376-83. DOI: 10.1023/a:1026647701477. View

14.

Spiegler G, Zodet M, Revicki D . Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia. Arch Fam Med. 2000; 9(7):624-30. DOI: 10.1001/archfami.9.7.624. View

15.

DeVault K, Castell D . Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005; 100(1):190-200. DOI: 10.1111/j.1572-0241.2005.41217.x. View

16.

Mathias S, Colwell H, Miller D, Pasta D, Henning J, Ofman J . Health-Related quality-of-life and quality-days incrementally gained in symptomatic nonerosive GERD patients treated with lansoprazole or ranitidine. Dig Dis Sci. 2001; 46(11):2416-23. DOI: 10.1023/a:1012363501101. View

17.

Stacey J, Miocevich M, Sacks G . The effect of ranitidine (as effervescent tablets) on the quality of life of GORD patients. Br J Clin Pract. 1996; 50(4):190-4, 196. View

18.

Velanovich V . Quality of life and severity of symptoms in gastro-oesophageal reflux disease: a clinical review. Eur J Surg. 2000; 166(7):516-25. DOI: 10.1080/110241500750008565. View

19.

Brazier J, Harper R, Jones N, OCathain A, Thomas K, Usherwood T . Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992; 305(6846):160-4. PMC: 1883187. DOI: 10.1136/bmj.305.6846.160. View

20.

Earnest D, Robinson M, Rodriguez-Stanley S, Ciociola A, Jaffe P, Silver M . Managing heartburn at the 'base' of the GERD 'iceberg': effervescent ranitidine 150 mg b.d. provides faster and better heartburn relief than antacids. Aliment Pharmacol Ther. 2000; 14(7):911-8. DOI: 10.1046/j.1365-2036.2000.00785.x. View